title: Research on chemotherapy efficacy of twist gene on cervical cancer cells to paclitaxel.
abstract: The silent Twist gene may increase the sensitivity of cervical cancer cells chemotherapy to paclitaxel, thus was a new idea to improve the efficacy of cancer chemotherapy. The aim was to explore chemotherapy sensitivity of silent Twist gene increased cervical cancer cells to paclitaxel through study the proliferation and apoptosis of cervical cancer Twist gene after paclitaxel treatment. Cervical carcinoma Caski cells and Hela cells was cultured in vitro, mRNA gene expression was detected by using semi-quantitative, fluorescence quantitative PCR, and transferred to Caski cells transiently, and affected with paclitaxel solution of five kinds of different concentrations of 0.001, 0.01, 0.1, 1, 10 umol/L respectively. Then the results of <0.05). Every 12h after 36 h, the expression inhibition rate in two groups of Caski cells that has transfected this study was Twist gene expression in Caski cells was higher than in Hela cells, which was of significant difference (p siRNA1 and siRNA2 were 20.3%, 38.2%, 33%, 24%, 68.6%, 50.8% respectively. After 48 h in five different concentrations of paclitaxel effect, the cell growth inhibition rate of group siRNA2 with the best transfection efficiency was obviously higher than that of negative control group and blank control group, and the growth inhibition rates showed concentration dependence (p<0.05). It can be concluded that Twist gene in Caski cell was of high expression and the silent Twist gene could inhibit Caski cell proliferation and promote its apoptosis, thus to improve the chemotherapy sensitivity of Caski cells.
authors.affiliation: Department of Oncology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou,China.
authors.forename: Zhenchang
authors.initials: Z
authors.lastname: Sun
authors.affiliation: Reproductive Center, the Second Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Zhang
authors.affiliation: Department of Oncology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
authors.forename: Yingying
authors.initials: Y
authors.lastname: Cui
authors.affiliation: Department of Oncology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou,China.
authors.forename: Liangxing
authors.initials: L
authors.lastname: Cheng
authors.affiliation: Department of Oncology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
authors.forename: Jingyu
authors.initials: J
authors.lastname: Cao
authors.affiliation: Department of Oncology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou,China.
authors.forename: Xiaolong
authors.initials: X
authors.lastname: Wu
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D005260:Female; D006367:HeLa Cells; D006801:Humans; D009687:Nuclear Proteins / Q000235:genetics*; D017239:Paclitaxel / Q000494:pharmacology*; D034741:RNA, Small Interfering / Q000235:genetics; D051879:Twist-Related Protein 1 / Q000235:genetics*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D009687:Nuclear Proteins; D034741:RNA, Small Interfering; C103173:TWIST1 protein, human; D051879:Twist-Related Protein 1; D017239:Paclitaxel